17α-estradiol, a structural variant of conventional estrogen, demonstrates remarkable male-specific longevity benefits through estrogen receptor alpha (ERα) pathways. This compound reduces adiposity, enhances insulin sensitivity, and preserves hepatic metabolic flexibility in male mice while producing only mild feminizing effects—a stark contrast to its potent sibling 17β-estradiol. The sexual dimorphism represents a fascinating biological puzzle: why does this estrogen variant preferentially benefit males when estrogens typically favor females? This selectivity suggests previously unknown mechanisms in sex-specific hormone signaling that could revolutionize our understanding of endocrine aging. The practical implications are substantial—17α-estradiol could offer men the metabolic and longevity benefits of estrogen supplementation without the unwanted feminizing consequences that make traditional estrogen therapy unsuitable. However, these findings remain in preclinical stages with mouse models, and the molecular basis for male bias remains unclear. The discovery challenges conventional assumptions about estrogen's role in male aging and opens promising avenues for developing sex-tailored anti-aging interventions that harness beneficial hormonal pathways without adverse effects.